Dec 23, 2024 7:00 am EST Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
Dec 19, 2024 7:00 am EST Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2024 7:00 am EST Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
Nov 20, 2024 7:00 am EST Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
Nov 19, 2024 7:00 am EST Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
Nov 8, 2024 7:00 am EST Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
Nov 7, 2024 7:00 am EST Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
Nov 6, 2024 7:00 am EST Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
Oct 29, 2024 4:30 pm EDT Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
